Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
The U.S. FDA issued a Form 483 with five observations
Facility designed to advance the next generation of imaging systems
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
Subscribe To Our Newsletter & Stay Updated